Loading…
Pharmacokinetics, mass balance, and metabolism of [14C]envonalkib (TQ-B3139), a novel ALK tyrosine kinase inhibitor, in healthy Chinese subjects
Ma, Sheng, Wang, Xin, Yan, Shu, Miao, Liyan, Wan, Xiaojing, Ding, Dawei, Yu, Ding, Diao, Xingxing, Wang, Xunqiang, Zhang, Hua
Published in Cancer chemotherapy and pharmacology (01.11.2024)
Published in Cancer chemotherapy and pharmacology (01.11.2024)
Get full text
Journal Article
Loading…
Evaluation of Bruton’s Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL)
Ouerdani, Aziz, Valenzuela, Belén, Treijtel, Nicoline, Haddish-Berhane, Nahor, Desphande, Sanjay, Srinivasan, Srimathi, Smith, Emma, Perez Ruixo, Juan José
Published in Cancer chemotherapy and pharmacology (01.12.2025)
Published in Cancer chemotherapy and pharmacology (01.12.2025)
Get full text
Journal Article
Loading…
Alterations in the tyrosine and phenylalanine pathways revealed by biochemical profiling in cerebrospinal fluid of Huntington’s disease subjects
Herman, Stephanie, Niemelä, Valter, Emami Khoonsari, Payam, Sundblom, Jimmy, Burman, Joachim, Landtblom, Anne-Marie, Spjuth, Ola, Nyholm, Dag, Kultima, Kim
Published in Scientific reports (11.03.2019)
Published in Scientific reports (11.03.2019)
Get full text
Journal Article
Loading…
Nonreceptor protein tyrosine phosphatases (NRPTPs) gene family associates with the risk of hepatocellular carcinoma in a Chinese hepatitis B virus‐related subjects
Shen, Na, Wang, Peng, Li, Ying, Zhu, Yaowu, Gong, Yajie, Zhong, Rong, Lu, Yanjun, Cheng, Liming
Published in Molecular carcinogenesis (01.08.2020)
Published in Molecular carcinogenesis (01.08.2020)
Get full text
Journal Article
Loading…
Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised double‐blind placebo‐controlled study
Dickson, Marion C., Walker, Alexandra, Grattan, Clive, Perry, Hayley, Williams, Nicola, Ratia, Nirav, Dewit, Odile, Gisbert, Sophie, Metz, Martin, Maurer, Marcus
Published in British journal of clinical pharmacology (01.12.2021)
Published in British journal of clinical pharmacology (01.12.2021)
Get full text
Journal Article
Loading…
Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects
Jing, Shan, Lin, Yang, Dockens, Randy, Marchisin, David, He, Bing, Girgis, Ihab G., Chimalakonda, Anjaneya, Murthy, Bindu, Aras, Urvi
Published in Dermatology and therapy (01.12.2023)
Published in Dermatology and therapy (01.12.2023)
Get full text
Journal Article
Loading…
Tyrosine Phosphatase–Related Islet Antigen 2(256–760) Autoantibodies, the Only Marker of Islet Autoimmunity That Increases by Increasing the Degree of BMI in Obese Subjects With Type 2 Diabetes
Buzzetti, Raffaella, Spoletini, Marialuisa, Zampetti, Simona, Campagna, Giuseppe, Marandola, Lidia, Panimolle, Francesca, Dotta, Francesco, Tiberti, Claudio
Published in Diabetes care (01.03.2015)
Published in Diabetes care (01.03.2015)
Get full text
Journal Article
Loading…
Human NACHT, LRR, and PYD domain–containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase
Liu, Xiao, Pichulik, Tica, Wolz, Olaf-Oliver, Dang, Truong-Minh, Stutz, Andrea, Dillen, Carly, Delmiro Garcia, Magno, Kraus, Helene, Dickhöfer, Sabine, Daiber, Ellen, Münzenmayer, Lisa, Wahl, Silke, Rieber, Nikolaus, Kümmerle-Deschner, Jasmin, Yazdi, Amir, Franz-Wachtel, Mirita, Macek, Boris, Radsak, Markus, Vogel, Sebastian, Schulte, Berit, Walz, Juliane Sarah, Hartl, Dominik, Latz, Eicke, Stilgenbauer, Stephan, Grimbacher, Bodo, Miller, Lloyd, Brunner, Cornelia, Wolz, Christiane, Weber, Alexander N.R.
Published in Journal of allergy and clinical immunology (01.10.2017)
Published in Journal of allergy and clinical immunology (01.10.2017)
Get full text
Journal Article
Loading…
Absolute bioavailability, biotransformation, and excretion of the bruton tyrosine kinase inhibitor TL-895 in healthy human subjects
Podoll, Terry, Allard, Martine, Krejsa, Cecile, Khorlin, Nick, Fong, Jonathan, Masten, Sue, Slatter, J. Greg
Published in Drug metabolism and pharmacokinetics (01.06.2025)
Published in Drug metabolism and pharmacokinetics (01.06.2025)
Get full text
Journal Article
Loading…
Abstract LB270: Absorption, distribution, metabolism and excretion (ADME) properties and absolute bioavailability of zongertinib, a selective oral HER2-specific tyrosine kinase inhibitor, in healthy male subjects
Joseph, David, Grempler, Rolf, Gan, Guanfa, Auclair, Adam, Maw, Hlaing, Laux, Ralf, Kiesling, Ralf, Wind, Sven, Minch, David
Published in Cancer research (Chicago, Ill.) (25.04.2025)
Published in Cancer research (Chicago, Ill.) (25.04.2025)
Get full text
Journal Article
Loading…
Tetrahydrobiopterin (BH4) treatment stabilizes tyrosine hydroxylase: Rescue of tyrosine hydroxylase deficiency phenotypes in human neurons and in a knock‐in mouse model
Jung‐KC, Kunwar, Tristán‐Noguero, Alba, Altankhuyag, Altanchimeg, Piñol Belenguer, David, Prestegård, Karina S., Fernandez‐Carasa, Irene, Colini Baldeschi, Arianna, Sigatulina Bondarenko, Maria, García‐Cazorla, Angeles, Consiglio, Antonella, Martinez, Aurora
Published in Journal of inherited metabolic disease (01.05.2024)
Published in Journal of inherited metabolic disease (01.05.2024)
Get full text
Journal Article
Loading…
Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective
van Leeuwen, Roelof W F, van Gelder, Teun, Mathijssen, Ron H J, Jansman, Frank G A
Published in The lancet oncology (01.07.2014)
Published in The lancet oncology (01.07.2014)
Get full text
Journal Article
Loading…
A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration
Poor, Stephen H., Weissgerber, Georges, Adams, Christopher M., Bhatt, Harit, Browning, David J., Chastain, James, Ciulla, Thomas A., Ferriere, Michael, Gedif, Kinfemichael, Glazer, Louis C., Joondeph, Brian C., Normand, Guillaume, Sheth, Veeral, Watters, Christie, Grosskreutz, Cynthia L.
Published in American journal of ophthalmology (01.07.2022)
Published in American journal of ophthalmology (01.07.2022)
Get full text
Journal Article
Loading…
Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects
Mu, Song, Tang, Zhiyu, Novotny, William, Tawashi, Manal, Li, Ta-Kai, Ou, Ying, Sahasranaman, Srikumar
Published in Cancer chemotherapy and pharmacology (01.02.2020)
Published in Cancer chemotherapy and pharmacology (01.02.2020)
Get full text
Journal Article
Loading…
A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease
Gallagher, Catherine L., Christian, Bradley T., Holden, James E., Dejesus, Onofre T., Nickles, Robert J., Buyan-Dent, Laura, Bendlin, Barbara B., Harding, Sandra J., Stone, Charles K., Mueller, Barb, Johnson, Sterling C.
Published in Movement disorders (01.09.2011)
Published in Movement disorders (01.09.2011)
Get full text
Journal Article
Loading…
XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib
Pietanza, M. Catherine, Lynch, Thomas James, Lara, Primo N., Cho, John, Yanagihara, Ronald H., Vrindavanam, Nandagopal, Chowhan, Naveed Mahfooz, Gadgeel, Shirish M., Pennell, Nathan A., Funke, Roel, Mitchell, Ben, Wakelee, Heather A., Miller, Vincent A.
Published in Journal of thoracic oncology (01.01.2012)
Published in Journal of thoracic oncology (01.01.2012)
Get full text
Journal Article
Loading…
Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects
Tran, Phi, Hanna, Imad, Eggimann, Fabian Kurt, Schoepfer, Joseph, Ray, Tapan, Zhu, Bing, Wang, Lai, Priess, Petra, Tian, Xianbin, Hourcade-Potelleret, Florence, Einolf, Heidi J.
Published in Xenobiotica (01.02.2020)
Published in Xenobiotica (01.02.2020)
Get full text
Journal Article
Loading…
Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor
Zhang, Xiaoshuai, Liu, Bingcheng, Huang, Jian, Zhang, Gongli, Liu, Xiaoli, Xu, Na, Li, Weiming, Du, Xin, Weng, Jianyu, Lin, Hai, Liang, Rong, Chen, Chunyan, Zhu, Huanling, Pan, Ling, Yang, Yun-fan, WANG, Xiaodong, Li, Guohui, Liu, Zhuogang, Liu, Zhenfang, Hu, Jianda, Liu, Chunshui, Fei, Li, Yang, Wei, Meng, Li, Gale, Robert Peter, Huang, Xiao Jun, Jiang, Qian
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
Loading…
Effects of LX4211, a Dual Sodium-Dependent Glucose Cotransporters 1 and 2 Inhibitor, on Postprandial Glucose, Insulin, Glucagon-like Peptide 1, and Peptide Tyrosine Tyrosine in a Dose-Timing Study in Healthy Subjects
Zambrowicz, Brian, Ogbaa, Ike, Frazier, Kenny, Banks, Phillip, Turnage, Anne, Freiman, Joel, Boehm, Kristi A., Ruff, Dennis, Powell, David, Sands, Arthur
Published in Clinical therapeutics (01.08.2013)
Published in Clinical therapeutics (01.08.2013)
Get full text
Journal Article
Loading…
The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects
Cao, Bei, Ma, Tingting, Zhang, Yuqiang, Huang, Lei, Lin, Hui, Jiang, Huanhuan, Zhao, Yu, Geng, Yan, Yang, Yuanxun, Cao, Sumin, Li, Juan
Published in Investigational new drugs (01.06.2024)
Published in Investigational new drugs (01.06.2024)
Get full text
Journal Article